Roche vs Pfizer vs Amgen and 1 More Revenue Comparison
Compare financial metrics side-by-side using real SEC EDGAR data
Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Roche 17.5245, Pfizer 15.034, Amgen 10.054, AstraZeneca 15.384.
* Roche reports semi-annually. Values are evenly split across both quarters within each half.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Roche, Pfizer, Amgen, AstraZeneca.| Metric | Roche | Pfizer | Amgen | AstraZeneca |
|---|---|---|---|---|
| Market Cap | $340.00B | $163.69B | $226.05B | $257.68B |
| Revenue | $35.05B | $15.03B | $10.05B | $15.38B |
| Cost of Revenue | $9.21B | $4.09B | $2.81B | $2.52B |
| Gross Profit | $25.84B | $10.94B | $7.24B | $12.86B |
| Operating Income | $10.90B | $4.71B | $3.51B | $3.16B |
| Net Income | $7.93B | $-246.00M | $2.38B | $2.51B |
| R&D Expense | $8.35B | $2.81B | $1.87B | $4.05B |
| Earnings Per Share | $1.23 | -$0.04 | $4.37 | $1.59 |
| Gross Margin | 73.7% | 72.8% | 72.0% | 83.6% |
| Operating Margin | 31.1% | 31.3% | 35.0% | 20.6% |
| Net Profit Margin | 22.6% | -1.6% | 23.6% | 16.3% |
| Free Cash Flow | $6.46B | $302.00M | $3.49B | $2.13B |
| Cumulative Free Cash Flow | $305.80B | $356.70B | $169.18B | $121.22B |
| Operating Cash Flow | $8.28B | $835.00M | $4.00B | $2.89B |
| Cash & Equivalents | $6.13B | $976.00M | $13.99B | $4.89B |
Prefer Sterling in Google
Add sterlingcharts.com as a preferred source so our charts can appear with a preferred badge in Google Top Stories, AI Mode, and AI Overviews.